Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase

Abstract Five‐fluorouracil (5‐FU) is a chemotherapeutic agent that is mainly metabolized by the rate‐limiting enzyme dihydropyrimidine dehydrogenase (DPD). The DPD enzyme activity deficiency involves a wide range of severities. Previous studies have demonstrated the effect of a DPYD single nucleotid...

Full description

Bibliographic Details
Main Authors:	Jihyun Kang, Andrew HyoungJin Kim, Inseung Jeon, Jaeseong Oh, In‐Jin Jang, SeungHwan Lee, Joo‐Youn Cho
Format:	Article
Language:	English
Published:	Wiley 2022-05-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.13203

Similar Items

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
by: Xuanyou Jin, et al.
Published: (2020-11-01)

Impact of Vancomycin‐Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin
by: Jung Sunwoo, et al.
Published: (2020-07-01)

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
by: Robert B. Diasio, et al.
Published: (2022-06-01)

In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase
by: Eiji Hishinuma, et al.
Published: (2020-07-01)

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
by: Raffaele Palmirotta, et al.
Published: (2019-03-01)

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.
by: Jaeseong Oh, et al.
Published: (2017-01-01)

EFFECTS OF CERTAIN DRUGS ON DIHYDROPYRIMIDINE DEHYDROGENASE ENZYME PURIFIED FROM BOVINE LIVER
by: Imdat Aygul, et al.
Published: (2017-07-01)

Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia
by: Hatouf H. Sukkarieh, et al.
Published: (2023-02-01)

Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression
by: Kruhøffer Mogens, et al.
Published: (2009-01-01)

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
by: Vijay M Patil, et al.
Published: (2016-01-01)

Dihydropyrimidine Dehydrogenase Gene Variation and Its Association with 5-Fluorouracil Toxicity in Colorectal Patients
by: Ebrahim Salehifar, et al.
Published: (2018-11-01)

Dihydropyrimidine dehydrogenase gene variation and its association with 5-fluorouracil toxicity in colorectal patients
by: ebrahim salehifar, et al.
Published: (2018-09-01)

Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes
by: MW Saif, et al.
Published: (2021-07-01)

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
by: Shigehiro Tsukahara, et al.
Published: (2022-05-01)

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients
by: Teh, Lay Kek, et al.
Published: (2013)

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine‐induced toxicity in an Asian population
by: Masashi Kanai, et al.
Published: (2023-04-01)

A pilot study using immunohistochemical staining to characterize dihydropyrimidine dehydrogenase expression in keratinocyte neoplasms
by: Ogechi Ikediobi, MD, PhD, et al.
Published: (2023-06-01)

Uncovering the roles of dihydropyrimidine dehydrogenase in fatty-acid induced steatosis using human cellular models
by: Kelly E. Sullivan, et al.
Published: (2022-08-01)

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
by: Theodore J. Wigle, et al.
Published: (2021-07-01)

Dihydropyrimidine dehydrogenase level and the redox status in patients with colorectal cancer are prognostic for adverse effects of fluoropyrimidines
by: Nadya G. Hristova-Avakumova, et al.
Published: (2021-01-01)

Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects
by: Inyoung Hwang, et al.
Published: (2022-08-01)

Single‐dose of LC51‐0255, a selective S1P1 receptor modulator, showed dose‐dependent and reversible reduction of absolute lymphocyte count in humans
by: Sang Won Lee, et al.
Published: (2022-04-01)

A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report
by: Anna Malekkou, et al.
Published: (2024-03-01)

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study
by: Côme De Metz, et al.
Published: (2024-03-01)

Dihydropyrimidine Dehydrogenase (DPD) as a Bridge between the Immune Microenvironment of Colon Cancers and 5-FU Resistance
by: Zhongze Cui, et al.
Published: (2023-04-01)

Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
by: Eva Gross, et al.
Published: (2008-01-01)

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients
by: Maarten J. Deenen, et al.
Published: (2013-01-01)

Evolution of Dihydropyrimidine Dehydrogenase Diagnostic Testing in a Single Center during an 8-Year Period of Time
by: Marieke J.H. Coenen, PhD, et al.
Published: (2019-01-01)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
by: JungJin Oh, et al.
Published: (2023-02-01)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
by: Madi, A, et al.
Published: (2018)

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
by: García-González X, et al.
Published: (2018-10-01)

Expression Levels of Thymidylate Synthase, Thymidylate Phosphorylase and Dihydropyrimidine Dehydrogenase in Head and Neck Squamous Cell Carcinoma: Preliminary Study
by: K. Aubry, et al.
Published: (2008-01-01)

Clinical Evaluation of Digital Therapeutics: Present and Future
by: Ki Young Huh, et al.
Published: (2022-07-01)

The necessary conduct: Exploratory multiregional clinical trials in East Asia
by: Inseung Jeon, et al.
Published: (2021-11-01)

Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment
by: Yewon Park, et al.
Published: (2022-06-01)

Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine
by: Mahshid Mohammadian, et al.
Published: (2019-08-01)

Tegafur–uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle
by: Daniel I.G. Cubero, et al.
Published: (2012-07-01)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
by: Joo Young Na, et al.
Published: (2022-11-01)

Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
by: Balzarini, J, et al.
Published: (2002)

Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy
by: Javier Guijarro-Eguinoa, et al.
Published: (2023-06-01)